Therapeutic Effect of Quadruple Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus Who Have Insulin Limitations

Prevalence of Anti Hyperglycemic Agents -Associated Oral Lichenoid Lesions in Type 2 Diabetes Mellitus Patients

Objective: This study aimed to estimate the prevalence of lichenoid reactions to Anti Hyperglycemic Agents. Materials and Methods: In this cross-sectional descriptive and analytic study, we examined the oral mucosa of 411 patients at the age of 29 to 85 in 3 groups who consumed various antihyperglycemic agents. Results: In overall, 31 patients had lichenoid reactions (12 patients taking glibe...

Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus

The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively revie...

Adherence to Hypoglycemic Medication among Insulin-Treated Patients with Type 2 Diabetes

Effects of insulin-oral hypoglycemic agents combined therapy in outpatients with type 2 diabetes.

To evaluate the efficacy of combined insulin-OHAs therapy in subjects with NIDDM who received treatment with OHAs and insulin alone, we selected 60 outpatients divided in two groups: Group A: 36 subjects treated with OHAs therapy that received insulin treatment for secondary failure; Group B: 24 subjects in which OHAs therapy was added to insulin regimen to avoid the effects of hyperinsulinizat...

Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus.

INTRODUCTION To analyze the efficacy and safety of empagliflozin combined with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. METHODS Pooled analysis of three phase III trials in patients with type 2 diabetes mellitus (n=1,801) who received placebo or empagliflozin 10 or 25mg once daily for 24 weeks, in combination with metformin, metformin+sulphonylurea or pioglita...